Clinical studies involving enfuvirtide are limited. No clinically significant drug interaction was reported when this medication was used in combination with the other antiretroviral drugs. In cell culture media assays, enfuvirtide exhibited additive-to-synergistic effects when it was combined with individual members of various antiretroviral agents, such as zidovudine (AZT, Retrovir drug, (Glaxo-SmithKline), lamivudine generic (3TC, [...]

In both studies, the addition of enfu-virtide to an optimized regimen provided significant antiretroviral and immunological results through 24 weeks of HIV treatment-experienced patients and those with multidrug-resistant HIV infection. TORO-1 showed a decrease in viral loads of 1.7 log10 in the enfuvir-tide/optimized background regimen group, whereas a decrease of 0.76 log10 was seen in [...]

Enfuvirtide is a synthetic peptide and is thus not bioavailable orally. Following a twice-daily subcutaneous injection of 30 to 90 mg, its bioavailability is approximately 84.3%. Comparable absorption of the 90-mg dose has been reported in different injection sites of the abdomen, thigh, and arm.

Acquired immunodeficiency syndrome (AIDS) continues to pose an overwhelming burden on public health. According to estimates from the Joint United Nations Programme on HIV.